Home>Topics>>Pozen Resubmits PA NDA, PDUFA In Two Months?
Pozen Resubmits PA NDA, PDUFA In Two Months?
Long Investing Ideas from Seeking Alpha
Thu, 3 Jul 2014
By Jason Napodano : On July 1, 2014, Pozen Inc ( POZN ) announced it had resubmitted the New Drug Application (NDA) for PA81/40 and PA325/40 to the U.S. FDA. Pozen noted that the FDA is expected to notify the company within 14 days of receipt of the NDA whether or not the submission will be ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.